Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03552107 · ClinicalTrials.gov registry record
Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic
A clinical trial of Obesity and Overweight, sponsored by Scripps Whittier Diabetes Institute.
- Completed
- Registry status
- 157
- Enrollment target
- 1
- Study location
NCT03552107: Completed study of Obesity and Overweight, sponsored by Scripps Whittier Diabetes Institute.
NCT03552107 is a study of Obesity and Overweight that has completed, run by Scripps Whittier Diabetes Institute. The registered enrollment target is 157 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03552107, a study of Obesity and Overweight, has completed, sponsored by Scripps Whittier Diabetes Institute.
- COMPLETED
- Registry status
- 157 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a retrospective, descriptive study that involves de-identified data consisting of weight changes, pertinent vital signs and laboratory values influenced by body weight, and healthcare utilization of patients prescribed lorcaserin at The Center for Weight Management at the Scripps Clinic in San Diego, CA.
Primary Outcome
Change in weight with Lorcaserin treatment
Conditions Studied
Interventions
- DRUG Lorcaserin
Study Locations (1)
California
- Scripps Whittier Diabetes Institute - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2019-04-11 |
What the finished NCT03552107 record still lists
NCT03552107 is an observational study that tracks outcomes without assigning an intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Lorcaserin is the first listed.
NCT03552107 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03552107 about?
NCT03552107 is a clinical study titled "Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic". This is a retrospective, descriptive study that involves de-identified data consisting of weight changes, pertinent vital signs and laboratory values influenced by body weight, and healthcare utilization of patients prescribed lorcaserin at The Center for Weight Management at the Scripps Clinic in S...
What is the current status of trial NCT03552107?
This trial is currently completed. The enrollment target is 157 participants. The study started on 2017-04-11. Estimated completion is 2019-04-11.
What conditions does trial NCT03552107 study?
This clinical trial studies the following conditions: Obesity, Overweight, Weight Loss.
What interventions are being tested in trial NCT03552107?
The interventions under investigation include: Lorcaserin (DRUG).
Who is sponsoring clinical trial NCT03552107?
This trial is sponsored by Scripps Whittier Diabetes Institute, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03552107 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03552107's enrollment target sits among peer trials
157 364th of 1053 higher than 689 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI